Skip to Main Content

Paper Details

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Blood
67
2021
Author NameAffiliation
Travis J Hollmann
Heiko Sch??derMemorial Sloan-Kettering Cancer Center
Giorgio InghiramiWeill Cornell Medical Center
David M WeinstockDana-Farber Cancer Institute
  • 1 - 4

Datasets

Release 1.2